12:00 AM
 | 
Jun 05, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Parecoxib: Phase II data; Phase III

In a study comparing 40 mg parecoxib to Roche Laboratories' Toradol ketorolac injectable NSAID or placebo in 94 healthy volunteers aged 65-75,...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >